SecBot SecBot
6-K ·Filed Apr 2, 2026

PHVS

Pharvaris N.V.
MIXED
Impact 6/10
Horizonmonths Processed7mo ago SEC0001830487-26-000012
Notable filing: 6-K
Actionable Insight ◆ Mixed

The positive clinical progress on CHAPTER-3 enrollment and maintained NDA timeline provide near-term catalysts, but the significant increase in R&D spending and widening net loss could pressure the balance sheet. Traders should monitor cash burn rate and upcoming topline data in Q3 2026 as key value drivers.

DirectionMixed
Confidencehigh
Horizonmonths

How the stock moved after the report

⚠ Clustered NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$28.56
T+0 close · Apr 2, 2026 · via day close
Latest settled
+21.08%
T+60 · $34.58
Vs SPY
+6.92%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Apr 2 $28.56entry
  2. T+1 · 8mo ago −0.67%α −1.14% · $28.37
  3. T+5 · 7mo ago −6.76%α −10.38% · $26.63
  4. T+20 · 7mo ago +8.58%α −1.30% · $31.01
  5. T+60 · 5mo ago +21.08%α +6.92% · $34.58
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Pharvaris reported its 2025 financial results and provided updates on its clinical development pipeline. Key developments include completion of enrollment in the pivotal CHAPTER-3 study for deucrictibant XR with topline data expected in Q3 2026, continued progress on the NDA submission for deucrictibant IR in 1H 2026, and ongoing enrollment in the CREAATE study for AAE-C1INH. The company reported €291.7 million in cash as of December 31, 2025, with full-year R&D expenses increasing to €124.5 million.

Key Facts

  • Enrollment completed in CHAPTER-3 pivotal study for deucrictibant XR; topline data expected in Q3 2026
  • NDA submission for deucrictibant IR remains on track for 1H 2026
  • Enrollment ongoing in CREAATE pivotal study for AAE-C1INH
  • Cash and cash equivalents of €291.7 million as of December 31, 2025
  • Full-year 2025 R&D expenses were €124.5 million, up from €98.6 million in 2024
  • Full-year 2025 net loss was €175.7 million, compared to €134.2 million in 2024

Financial Impact

R&D expenses increased 26.3% year-over-year to €124.5 million, while net loss widened to €175.7 million from €134.2 million in 2024. Cash position increased to €291.7 million from €281 million at end of 2024.

cashr&d expensesnet lossdilution

Risk Factors

  • Increased R&D spending could accelerate cash burn
  • Clinical trial results may not meet expectations
  • Regulatory approval timelines could slip
  • Competition in HAE treatment market

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations

Investment Themes

Documents Analyzed

This report is based on 5 SEC documents filed with EDGAR.

DocumentAccession Number
6-K Filing (Primary)0001830487-26-000012
Document: pr_fin_results_2025.htm0001830487-26-000012
Document: 0001830487-26-000012-index-headers.html0001830487-26-000012
Document: 0001830487-26-000012-index.html0001830487-26-000012
Document: 0001830487-26-000012.txt0001830487-26-000012

Track record

51 reports on PHVS

Performance horizon

15 of 18 bullish or bearish reports moved the stock their way by T+5. Best: +23.73% at T+20 after the Sep 17, 2026 report. 17 of 19 went positive at some point.

Filters
  1. Nov 16, 2026today SC 13G Neutral 4/10 Entry $33.19 Now $32.44 −2.26% settles Nov 23
  2. Nov 13, 20263d ago SC 13G/A Bearish 5/10 Entry $33.59 Now $32.44 +3.42% settles Nov 23
  3. Nov 12, 20264d ago Press Release Bullish 7/10 Entry $33.83 Now $32.44 −4.11% settles Nov 19
  4. Nov 12, 20264d ago 6-K Neutral 4/10 No price data
  5. Nov 12, 20264d ago Press Release Neutral 5/10 Entry $33.83 Now $32.44 −4.11% settles Nov 19
  6. Sep 25, 20267w ago Insider Cluster Bearish 6/10 Entry $32.02 to $31.19 Now $32.44 −1.31% ▲ +2.59% +2.37% vs SPY
  7. Sep 24, 20267w ago Insider Cluster Bearish 7/10 Entry $32.99 to $31.01 Now $32.44 +1.67% ▲ +6.00% +5.59% vs SPY
  8. Sep 24, 20267w ago Insider Cluster Bearish 5/10 Entry $32.99 to $31.01 Now $32.44 +1.67% ▲ +6.00% +5.59% vs SPY
  9. Sep 23, 20267w ago Insider Cluster Bearish 6/10 Entry $33.07 to $31.72 Now $32.44 +1.91% ▲ +4.08% +3.41% vs SPY
  10. Sep 21, 20268w ago Insider Cluster Bearish 5/10 Entry $36.02 to $31.91 Now $32.44 +9.94% ▲ +11.41% +10.39% vs SPY
Showing 10 of 51

US Market Status

Market Closed · Opens in 6h 38m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Apr 2, 2026